528 results on '"Lebbé, Céleste"'
Search Results
2. Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1
3. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
4. When to stop immunotherapy for advanced melanoma: the emulated target trials
5. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
6. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
7. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
8. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
9. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
10. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
11. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
12. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
13. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
14. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
15. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
16. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
17. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
18. Hyperprogression in advanced melanoma is not restricted to immunotherapy
19. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
20. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
21. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
22. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
23. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
24. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
25. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
26. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
27. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
28. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
29. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
30. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
31. Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction
32. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
33. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort
34. Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK
35. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
36. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
37. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
38. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
39. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
40. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
41. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
42. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
43. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal
44. Deep cutaneous fungal infections in solid-organ transplant recipients
45. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
46. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
47. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
48. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
49. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
50. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.